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Accurate survival estimates are needed for guiding cancer control efforts in sub-Saharan Africa, but previous
studies have been hampered by unknown biases due to excessive loss to follow-up (LTFU). In the African Breast
Cancer—Disparities in Outcomes Study, a prospective breast cancer cohort study, we implemented active mobile
health follow-up, telephoning each woman or her next-of-kin (NOK) trimonthly on her mobile phone to update
information on her vital status. Dates of every contact with women/NOK were analyzed from diagnosis in 2014–
2017 to the earliest of September 1, 2018, death, or 3 years postdiagnosis. The cumulative incidence of being
LTFU was calculated considering deaths as competing events. In all, 1,490 women were followed for a median
of 24.2 (interquartile range (IQR), 14.2–34.5) months, corresponding to 8,529 successful contacts (77% of total
contacts) with the women/NOK. Median time between successful contacts was 3.0 (IQR, 3.0–3.7) months. In
all, 71 women (5.3%) were LTFU at 3 years: 0.8% in Nigeria, 2.2% in Namibia, and 5.6% in Uganda. Because of
temporary discontinuity of active follow-up, 20.3% of women were LTFU after 2 years in Zambia. The median time
to study notification of a death was 9.1 (IQR, 3.9–14.0) weeks. Although the present study was not a randomized
controlled trial, in this cancer cohort with active mobile health follow-up, LTFU was much lower than in previous
studies and enabled estimation of up-to-date and reliable cancer survival.
breast cancer; cancer survival; loss to follow-up; mobile health; prospective studies; sub-Saharan Africa
Abbreviations: ABC-DO, African Breast Cancer—Disparities in Outcomes; CI, confidence interval; HIV, human immunodeficiency
virus; IQR, interquartile range; LTFU, loss/lost to follow-up; mHealth, mobile health; NOK, next-of-kin; SHR, subhazard ratio; SIM,
subscriber identity module; SSA, sub-Saharan Africa.
Accurate cancer survival estimates are needed for sub-
Saharan Africa (SSA) in order to gauge the magnitude of
survival improvements needed, especially for potentially
curable and common cancers like breast cancer (1). The In-
ternational Agency for Research on Cancer and the African
Cancer Registry Network lead the collection of population-
based cancer data across the region (2), but there remains a
paucity of reliable survival estimates unhampered by exces-
sive loss to follow-up (LTFU) (3–13). In particular, in stud-
ies with retrospective follow-up approaches applied within
health information systems with incomplete or no death
registration, high LTFUs may represent large clinical losses
and lack of treatment completion; thus, LTFU does not
occur at random and survival may be overestimated. In
the African Cancer Registry Network’s recent retrospective
estimates of breast cancer survival from 14 cancer registries,
follow-up was conducted primarily through clinical records
supplemented with active tracing (i.e., telephone contacts,
home visits): 1-year LTFU ranged from 0% in 3 registries
(1 with record linkage to a national death register) to 8%–
19% in 4 registries and 20%–45% in the remaining 7 (12).
Further, in a retrospective South African breast cancer study
in which the cohort was followed through medical rec-
ords alone, the 42% of women who were LTFU at 3 years
were more likely to have had advanced disease at diagnosis
than women who were not LTFU, which is suggestive of
biased survival estimates (11). In another study, among
1,328 Kaposi sarcoma patients diagnosed in 2009–2012 in
33 clinics across 5 countries and followed using medical
records, the “nominal” proportion of 22% deaths at 2 years
was clouded by 40% LTFU (9). However, a subsequent
report by Semeere et al. (10) showed that the majority of
those losses could be successfully traced through a combi-
nation of telephone calls and physical tracking via the local
clinics involved.
Cognizant of the need to minimize LTFU, investigators
designed the African Breast Cancer—Disparities in Out-
comes (ABC-DO) Study, a multicountry breast cancer co-
hort study, to employ a highly active follow-up approach
using mobile telephones, by means of mobile-Health
(mHealth) technology (14). Management of the follow-
up schedule for over 1,500 women was implemented via
a tailor-made mHealth application. Herein, we evaluate the
real-life implementation of this follow-up approach in terms
of the proportion LTFU, the profile of women who were
LTFU, and the timeliness of death notifications to the study.
The practicalities and challenges of implementing mHealth
follow-up in SSA settings are also discussed.
METHODS
Ethics
The ABC-DO Study protocol was approved by the ethics
committees of all involved institutions: the International
Agency for Research on Cancer (Lyon, France); the London
School of Hygiene and Tropical Medicine (London, United
Kingdom); the Federal Medical Centre Owerri (Owerri,
Nigeria); the Abia State University Teaching Hospital (Aba,
Nigeria); the University of Zambia (Lusaka, Zambia);
the University of the Witwatersrand (Johannesburg, South
Africa); the Uganda National Council for Science and Tech-
nology (Kampala, Uganda); and the Ministry of Health and
Social Services of Namibia (Windhoek, Namibia). All par-
ticipants provided written or fingerprint informed consent.
Study design and setting
The ABC-DO Study is a prospective, hospital-based bre-
ast cancer cohort study spanning 5 SSA countries. The ABC-
DO protocol has been published elsewhere (14). Briefly,
all women aged ≥18 years who were newly diagnosed
with breast cancer (with histological/cytological (90%)
or clinical confirmation) at participating hospitals from
September 2014 to early 2017 were invited to participate
(99% participation rate). Women were included irrespective
of ethnicity, language spoken, and area/country of residence.
The present analysis includes the ABC-DO sites in Namibia,
Zambia, Nigeria, and Uganda, which implemented the same
follow-up protocol, but does not include the South African
site, which used a different protocol.
Participation involved completion of a face-to-face base-
line questionnaire, consent to use clinical records and tumor
blocks, and agreement to be regularly contacted by mobile
phone. For this anticipated contact, up to 6 cell phone num-
bers for each woman (4 per woman plus 2 for her next-
of-kin (NOK)) were obtained. Women who did not have a
cell phone were provided with a basic handset (an Inter-
net connection or smartphone was required on the partici-
pant’s handset). Each woman was also provided with 2 cards
with the study research assistant’s phone number on them,
enabling her and/or her NOK to contact the local study team
at any time.
ABC-DO follow-up protocol and its implementation via
mHealth
A highly active follow-up protocol of trimonthly phone
calls to each woman was planned following a standardized
study protocol. Calls were made by one of the local research
assistants, from their smartphone to the woman’s basic (or
otherwise) cell phone. If the assistant did not succeed in
reaching the woman after several attempts over 2–3 weeks,
they contacted the NOK (see Web Figure 1, available at
https://academic.oup.com/aje). At each of these contacts,
vital status or contact details were updated and quality-of-
life information was obtained. Vital status was also updated
during the woman’s in-person visits to the hospital, when-
ever the woman or her NOK phoned the research assistant,
and via treatment data. Where possible, each woman was
followed by the same research assistant for every trimonthly
contact. Translators assisted in various languages during
follow-up calls as appropriate—for example, in various
indigenous languages in Namibia, in English, in Afrikaans,
and, for Angolan patients, in Portuguese.
mHealth technologies were also used for data collection
and study management. The follow-up call questionnaire
was administered from, and responses were instantaneously
entered into, a tailored ABC-DO mobile application (app).
This app was implemented for Android by Mobenzi Tech-
nologies Pty. (Cape Town, South Africa) and installed on
research assistants’ smartphones/tablets. All questionnaires
(including baseline, treatment, follow-up calls, and hospital
visits) were programmed into the app, allowing for real-time
data capture (Web Figure 1). Upon interview completion,
data were automatically uploaded to a secure server, leaving
no data on the phone. Each full-time research assistant had
up to 400 women to follow on a trimonthly basis (approx-
imately 133 contacts/month; 35 contacts/week). Manage-
ment of this dynamic schedule of follow-ups was complex;
thus, the mHealth app included an auto-updated list of
women who were due to receive a follow-up call. A woman
was removed from the list only when her vital status was
updated (via her or her NOK), and she was permanently
removed only upon receipt of death information or upon her
wish to discontinue participation.












No. %b No. % No. % No. % No. %
Age at diagnosis, yearsc 50.3 (13.7) 53.4 (14.7) 48.7 (12.3) 48.3 (12.7) 49.9 (14.8)
Age group, years
<35.0 183 12 46 10 51 13 56 13 30 15
35.0–44.9 390 26 99 21 117 30 123 29 51 25
45.0–54.9 420 28 130 27 106 27 129 31 55 27
55.0–64.9 269 18 102 21 72 19 65 15 30 15
≥65.0 228 15 104 22 41 11 48 11 35 17
Age, yearsc 50.3 (13.7) 53.4 (14.7) 48.7 (12.3) 48.3 (12.7) 49.9 (14.8)
Tumor stage
I or II 512 34 211 44 89 23 144 34 68 34
III 672 45 202 42 209 54 178 42 83 41
IV 207 14 68 14 61 16 65 15 13 6
Missing data 99 7 0 0 28 7 34 8 37 18
Socioeconomic positiond
Low 655 44 170 35 167 43 248 59 70 35
Medium 501 34 173 36 166 43 89 21 73 36
High 334 22 138 29 54 14 84 20 58 29
Distance to hospital, kme 67 (6–289) 375 (83–572) 7 (2–30) 90 (15–193) 210 (8–417)
HIV-positive 146 10 56 12 9 2 48 11 33 16
Any non-HIV comorbidityf 754 51 256 53 294 76 131 31 73 36
Urban residency 797 53 307 64 250 65 110 26 130 65
Knowing someone with breast cancer 672 45 246 51 179 46 205 50 42 21
Not married 736 49 301 63 126 33 223 53 86 43
Lower educational levelg 1,171 79 392 82 250 65 370 88 159 79
Unskilled employmenth,i 1,036 70 309 66 254 66 320 76 153 76
Belief that breast cancer is
treatable
801 54 380 79 124 32 164 39 133 66
Belief in spiritual medicinei 1,023 70 349 78 298 77 202 48 174 87
Belief in traditional medicinei 362 25 60 13 88 23 162 38 52 26
Abbreviations: HIV, human immunodeficiency virus; IQR, interquartile range; SD, standard deviation.
a Participating hospitals in each country were as follows: Namibia—AB May Cancer Care Centre and Windhoek Central Hospital; Nigeria—
Federal Medical Center Owerri, Abia State University Teaching Hospital, and Marantha Clinic, Aba; Uganda—Mulago Hospital and Uganda
Cancer Institute, Kampala; Zambia—University Teaching Hospital and Cancer Diseases Hospital, Lusaka.
b Column percentages.
c Values are expressed as mean (standard deviation).
d Low, medium, and high socioeconomic position were calculated, by country, as tertiles of a socioeconomic position score (range,
1–10) based on the following self-reported possessions and facilities: home ownership; indoor water; f lush toilet; electricity; vehicle; refrigerator;
landline telephone; gas or electric stove; and bed.
e Values are expressed as median (interquartile range).
f Assessed comorbid conditions included hypertension, diabetes, chronic obstructive pulmonary disease, hepatitis, heart disease, anemia,
asthma, and tuberculosis.
g Lower than tertiary level.
h Including 277 housewives.
i Values were missing in Namibia due to a data collection error. There were 12 missing values for employment and 33 missing values each
for belief in spiritual medicine and belief in traditional medicine.











(n = 201)mHealth Follow-up Indicator
No. %a No. % No. % No. % No. %
Access to a mobile phoneb 1,340 90 450 94 384 99 312 74 193 96
NOK contact number provided 1,431 96 444 92 383 99 406 96 198 99
mHealth database entries
All entries 11,136 100 5,369 100 1,853 100 3,032 100 882 100
Woman reached—FU interview
conducted
7,358 66 3,016 56 1,284 69 2,629 87 429 49
Woman reached—interview rescheduled 374 3 330 6 15 1 19 1 10 1
NOK confirmed that woman was alive 160 1 53 1 20 1 15 0.5 72 8
NOK notified study of woman’s death 637 6 158 3 211 11 201 7 67 8
Patient/NOK not reached 2,607 23 1,812 34 323 17 168 6 304 34
Time between consecutive follow-up
interviews, monthsc
3.0 (3.0–3.7) 3.2 (3.0–3.9) 3.7 (3.2–4.9) 3.0 (3.0–3.0) 3.3 (3.0–4.6)
Call duration, minutesc
When FU interview was conducted 12.4 (8.4–21.2) 8.8 (7.1–11.8) 17.0 (11.9–27.0) 19.9 (12.6–33.1) 18.1 (12.1–26.7)
When FU interview was not conducted 2.5 (1.5–5.0) 1.8 (1.4–2.8) 3.9 (2.6–6.9) 8.6 (1.7–16.0) 5.3 (3.0–10.4)
Abbreviations: FU, follow-up; NOK, next-of-kin.
a Column percentages.
b Either the participant’s own phone or someone else’s (e.g., family member).
c Values are expressed as median (interquartile range).
Statistical analysis
We analyzed risk of being LTFU in a time-to-event analy-
sis, starting from the woman’s diagnosis date (earliest of the
date of histology/cytology sample collection or the baseline
interview) to the earliest of 3 years postdiagnosis, the date
of death, or the closing date for the present analysis, namely
September 1, 2018 (i.e., 6 months before data extraction
to allow for follow-up contacts in the 3-monthly protocol).
A woman was considered LTFU if her vital status was
not known on the closing date. The cumulative incidence
percentage of LTFU and its 95% confidence interval were
calculated considering deaths as competing risks (referred
to hereafter as LTFUCR), using the “stcompet” command in
Stata (StataCorp LLC, College Station, Texas). Competing-
risks regression analyses, adjusted for tumor stage, age at
diagnosis, and socioeconomic position, were performed to
identify correlates of being LTFU, and subhazard ratios were
estimated using the Stata command “stcrreg.” Predictor vari-
ables are described in the Web Appendix. For some women,
reasons for LTFU were noted by the research assistant in an
optional open text field in the follow-up questionnaire. These
data were reviewed, and reasons are presented descriptively.
Median values and their interquartile ranges or mean
values and their 95% confidence intervals, time between
consecutive follow-up contacts, and time between the date
of a woman’s death (from any cause) and the date of its
notification to the study were estimated. For the latter, only
deaths that occurred earlier than September 1, 2018, were
considered in the analysis.
RESULTS
In all, 1,541 women were enrolled in the 4 countries
included in the present analysis. Of these, 51 (3.3%) were
not included because of an indication that they may not have
been incident cases, since they were told they had breast
cancer or had a biopsy conducted more than 24 months prior
to their baseline interview. Of the remaining 1,490 women
with breast cancer, 481 were from Namibia, 421 were from
Uganda, 387 were from Nigeria, and 201 were from Zambia
(Table 1). All women were Black African, except in Namibia
(80% Black, 20% White/mixed-race). Mean age at diagnosis
was 50 (standard deviation, 13.7) years, and most women
were diagnosed with stage III cancer. More than 50% of
the women lived in urban areas, apart from those in Uganda
(26%). Most women (70%) did not hold a skilled job.
Follow-up using mHealth technologies
All 1,490 women provided at least 1 personal contact
number, and 1,431 (96%) provided one for their NOK
(Table 2). The median follow-up time was 24.2 (interquartile
Figure 1. Mean duration (months) between consecutive successful follow-up calls among ABC-DO cohort members known to still be alive, by
follow-up number and total number of follow-up contacts (squares, participants with <10 follow-up interviews; triangles, participants with ≥10
follow-up interviews), African Breast Cancer—Disparities in Outcomes Study, 2014–2018. Mean values, 95% confidence intervals (CIs), and
numbers of women are provided in Web Table 1. Follow-up call number 1 was the first call scheduled 3 months after the baseline interview. Bars,
95% CIs.
line with the trimonthly protocol. However, the length of
this interval decreased over time, with a stronger gradient
in the mean (from 3.8 (95% CI: 3.7, 3.9) months between
the first and second contacts to 3.1 (95% CI: 3.0, 3.1)
months between the ninth and 10th contacts) than in the
median (from 3.2 (IQR, 3.0–3.9) months to 3.0 (IQR, 3.0–
3.0) months, respectively). This time trend reflected a “self-
selection” process whereby terminal and difficult-to-trace
women were lost or died over time. Consequently, although
the mean length between consecutive follow-up interviews
decreased gradually for the whole cohort, it remained con-
stant for the subset of women who completed at least 10
interviews (Figure 1).
A cumulative total of 19 women had become LTFU by
the end of year 1 and 58 by the end of year 2, yielding
LTFUCR percentages of 1.3% (95% CI: 0.8, 1.9) and 4.0%
(95% CI: 3.1, 5.1), respectively (Table 3, Figure 2). At
3 years, LTFUCR percentages were low in Nigeria (n = 3;
LTFUCR = 0.8%, 95% CI: 0.2, 2.2) and Namibia (n = 10;
LTFUCR = 2.2%, 95% CI: 1.1, 3.9) and slightly higher in
Uganda (n = 21; LTFUCR = 5.6%, 95% CI: 3.6, 8.3).
Because of a later commencement of recruitment, LTFUCR
in Zambia could only be analyzed up to 2 years, by which
time losses were already much higher than in other coun-
tries (n = 37; LTFUCR = 20.3%, 95% CI: 14.8, 26.5).
Reasons for LTFU were known for 46 women (65%).
The most commonly reported reason was an unavailable
range (IQR), 14.2–34.5) months (31.1 months excluding 
deaths). Up to this time point, 11,136 mHealth follow-up 
entries (attempted calls plus those where the woman/NOK 
was successfully reached) were logged into the mHealth 
platform. Of these, 7,358 (66%) were completed interviews 
with the woman herself, 374 (3%) were instances where the 
assistant reached the participant but she asked to reschedule 
the interview, 160 (1%) were contacts with the NOK indi-
cating that the woman was alive, and 637 (6%) were death 
notifications. The remaining 2,607 entries (23%) were un-
successful contact attempts, many of which were subse-
quently followed by a successful contact. The median du-
ration of a (successful) call with the woman was 12.4 (IQR, 
8.4–21.2) minutes. At the study closing date, half of the 
cohort had completed at least 5 follow-up interviews (IQR, 
2–8), and 195 women (13%) had completed 10 or more, 
whereas 132 women (9%) had none due to early death 
(n = 127, at a median of 2.8 (IQR, 1.4–5.0) months). Only 5 
(0.3%) were early LTFUs with no follow-up contacts after 
the baseline interview. Updated follow-up status was almost 
always obtained through the mHealth phone contacts, but 
for 15 women their last known date alive was sourced from 
medical records.
The median and mean number of months between con-
secutive contacts that resulted in successful follow-up inter-
views with the woman were 3.0 (IQR, 3.0–3.7) and 3.6 (95%
confidence interval (CI): 3.6, 3.7), respectively—that is, in
Table 3. Numbers and Proportionsa of Women Lost to Follow-up According to Time Since Diagnosis, Overall and by Study Site, African Breast
Cancer—Disparities in Outcomes Study, 2014–2018




Followed No. % 95% CI No. % 95% CI No. % 95% CI
All 1,490 19 1.3 0.8, 1.9 58 4.0 3.1, 5.1 71 5.3 4.2, 6.6
Namibia 481 0 0 0, 0.8 5 1.0 0.4, 2.3 10 2.2 1.1, 3.9
Nigeria 387 0 0 0, 0.9 3 0.8 0.2, 2.2 3 0.8 0.2, 2.2
Uganda 421 6 1.4 0.6, 2.9 13 3.1 1.7, 5.1 21 5.6 3.6, 8.3
Zambia 201 13 6.5 3.6, 10.4 37 20.3 14.8, 26.5 —b — —
Abbreviations: CI, confidence interval; LTFU, lost to follow-up.
a Cumulative incidence of being LTFU considering death as a competing risk (LTFUCR).
b Because of later recruitment, Zambian patients had not yet completed the third year of follow-up (n = 37 LTFU) at the closing date of the
study.
telephone number (83%), followed by a discontinued,
incorrect, or changed number (n = 5 (11%)). Two patients
(4%) left the country, while withdrawal from the study
was reported for 1 woman (2%). In Namibia, of the 10
LTFU participants, 6 were women from neighboring Angola
and Zimbabwe. Although it was not noted by the research
assistant, it seems likely that they returned to their home
countries after cancer treatment.
Determinants of being LTFU were examined in the coun-
tries where there were sufficient numbers of women lost—
that is, in Zambia (n = 37 lost) and in Namibia (n = 10)
and Uganda (n = 21) combined—but such analyses were
not relevant for Nigeria due to only 3 losses. The risk of
being LTFU decreased with increasing age at breast cancer
diagnosis in Zambia (per 10-year increment in age, sub-
hazard ratio (SHR) = 0.74, 95% CI: 0.59, 0.92) (Table 4)
and in Uganda and Namibia (SHR = 0.76, 95% CI: 0.57,
1.01). In Zambia only, LTFU was also lower with increasing
socioeconomic position (per tertile, SHR = 0.64, 95% CI:
0.42, 0.98) (Table 4) and for human immunodeficiency virus
(HIV)-positive women compared with HIV-negative women
(SHR = 0.30, 95% CI: 0.12, 0.86) (Table 5). In Uganda and
Namibia, urban residency was associated with a higher risk
of being LTFU (SHR = 2.15, 95% CI: 1.07, 4.34) (Table 5).
Risk of being LTFU was not associated with tumor stage at
diagnosis; however, there was weak evidence that it may
have been higher among those with missing stage informa-
tion. No other associations with risk of being LTFU were
found, but the 95% confidence intervals for most estimates
were wide because of the small number of LTFUs in most
settings.
Notification of deaths
Until September 1, 2018, the study had gained informa-
tion on 676 deaths. These deaths were reported to the study
a median of 9.1 (IQR, 3.9–14.0) weeks after their occur-
rence. Country-specific intervals were shorter in Namibia
and Uganda (median lag times of 7.9 (IQR, 3.4–11.6) weeks
and 7.7 (IQR, 2.7–11.4) weeks, respectively) than in Nigeria
Figure 2. Cumulative incidence of being lost to follow-up in the African Breast Cancer—Disparities in Outcomes Study, by country, 2014–2018.
Table 4. Associations of Tumor Stage, Age, Socioeconomic Position, and Residential Distance From a Hospital With Being Lost to Follow-upa,
African Breast Cancer—Disparities in Outcomes Study, 2014–2018
Uganda and Namibia Zambia
Variable
No. % SHRb 95% CI No. % SHRb 95% CI
Tumor stage
I or II 13 4 1.00 Referent 10 14 1.00 Referent
III 13 3 0.85 0.39, 1.84 16 19 1.12 0.51, 2.47
IV 2 2 0.35 0.78, 1.58 0 0
Missing data 3 9 1.86 0.51, 6.76 11 30 1.72 0.74, 4.01
Age group at diagnosis, years
<35.0 8 8 2.57 0.97, 6.84 9 30 1.06 0.45, 2.46
35.0–44.9 7 3 1.02 0.37, 2.84 10 20 0.83 0.36, 1.91
45.0–54.9 8 3 1.00 Referent 15 27 1.00 Referent
55.0–64.9 7 4 1.50 0.56, 4.07 1 3 0.13 0.02, 0.99
≥65.0 1 1 0.24 0.03, 2.00 2 6 0.15 0.03, 0.68
Age, per 10-year increment 0.76 0.57, 1.01 0.74 0.59, 0.92
Distance to hospital, per 100-km increment 1.15 1.03, 1.28 0.92 0.76, 1.11
Socioeconomic positionc
Low 13 3 1.00 Referent 14 20 1.00 Referent
Middle 10 4 1.50 0.69, 3.28 16 22 0.84 0.39, 1.84
High 8 4 1.23 0.50, 3.00 7 12 0.38 0.15, 0.97
Socioeconomic position, per tertile increment 1.13 0.75, 1.69 0.64 0.42, 0.98
Abbreviations: CI, confidence interval; SHR, subhazard ratio.
a Assessed using SHRs in a competing-risks survival model. Because of the small numbers of women lost to follow-up in Nigeria (n = 3 at
3 years), Nigeria was not included in this analysis.
b SHR estimated from a competing-risk regression model with death as a competing event, adjusted for population group (Uganda and
Namibia), tumor stage at diagnosis, socioeconomic position, and age (linear increase per year).
c Low, medium, and high socioeconomic position were calculated, by country, as tertiles of a socioeconomic position score (range, 1–10)
based on the following self-reported possessions and facilities: home ownership; indoor water; f lush toilet; electricity; vehicle; refrigerator;
landline telephone; gas or electric stove; and bed.
breast cancer cohort study in SSA. Active follow-up was
conducted on a trimonthly basis via calls to a participant’s or
her NOK’s mobile phone, from the study research assistant’s
smartphone/tablet, and during the call, assistants entered
real-time updated information on vital status and quality
of life. Using this mHealth follow-up protocol, by the end
of the first 3 years, LTFUs were below 10% overall and
less than 3% in 2 countries. Regularity of contact was
crucial to achievement of low LTFU, as evidenced by the
much higher LTFU in Zambia. In this setting, a change in
fieldwork personnel led to a disruption in active follow-up;
that is, there was a period of approximately 5 months during
which women were not contacted. Although active follow-
up was gradually resumed upon employment of new study
personnel, the disruption in regular calls led to irreversible
losses of some women. mHealth contacts also achieved
impressive timeliness of death notification, with a median
of 9 weeks. Research assistants did not feel that this contact
with the NOK soon after a woman’s death was insensitive or
an inconvenience to the NOK or the family.
(median, 10.9 (IQR, 5.9–17.3) weeks) and Zambia (median, 
11.9 (IQR, 5.3–24.3) weeks) (Figure 3). The length of this 
time interval did not vary by factors investigated, including 
age, calendar period, urban/rural residence, or woman’s 
educational level (not shown), but it was longer for foreign 
patients receiving treatment in Namibia (a median of 20.1 
(IQR, 7.2–33.2) weeks among 24 deaths).
DISCUSSION
With rapidly growing mobile phone coverage, mHealth 
has the potential to transform health and health research 
in Africa. Its uses are widespread, including in pathology, 
multidisciplinary oncology meetings, and the setup of cohort 
studies for noncommunicable diseases (15). mHealth has 
been incorporated as a research tool in the study of infectious 
diseases and noncommunicable diseases, usually embedded 
in disease surveillance programs, but less often for active 
follow-up (16, 17). In the present study, we utilized mHealth 
for almost every aspect of the first multicountry prospective
Table 5. Associations of Baseline Sociocultural Factors and Comorbidity With Being Subsequently Lost to Follow-upa, African
Breast Cancer—Disparities in Outcomes Study, 2014–2018
Uganda and Namibia Zambia
Variable
No. % SHRb 95% CI No. % SHRb 95% CI
HIV-positive
No 3 3 1.00 Referent 34 20 1.00 Referent
Yes 28 4 0.80 0.22, 2.93 3 9 0.30 0.12, 0.86
Any comorbidityc
No 23 4 1.00 Referent 25 20 1.00 Referent
Yes 8 2 0.60 0.26, 1.41 12 16 1.43 0.67, 3.04
Urban residency
No 13 3 1.00 Referent 13 18 1.00 Referent
Yes 18 4 2.15 1.07, 4.34 24 18 1.17 0.47, 2.90
Knowing someone with breast cancer
No 14 3 1.00 Referent 29 18 1.00 Referent
Yes 17 4 1.16 0.53, 2.54 8 19 1.08 0.46, 2.53
Not married
No 15 4 1.00 Referent 23 20 1.00 Referent
Yes 16 3 0.93 0.45, 1.92 14 16 1.07 0.55, 2.08
Low educational leveld
No 25 3 0.88 0.34, 2.27 31 20 1.20 0.44, 3.30
Yes 6 4 1.00 Referent 6 14 1.00 Referent
Unskilled employmente,f
No 17 3 0.54 0.27, 1.09 31 20 1.35 0.53, 3.41
Yes 14 5 1.00 Referent 6 13 1.00 Referent
Belief that breast cancer is treatable
No 17 3 1.00 0.47, 2.08 26 20 1.02 0.48, 2.16
Yes 14 4 1.00 Referent 11 16 1.00 Referent
Belief in spiritual medicinef
No 14 3 0.57 0.26, 1.26 31 18 1.10 0.49, 2.50
Yes 17 5 1.00 Referent 6 22 1.00 Referent
Belief in traditional medicinef
No 7 3 0.70 0.29, 1.71 6 12 0.54 0.22, 1.36
Yes 24 4 1.00 Referent 31 21 1.00 Referent
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; SHR, subhazard ratio.
a Assessed using SHRs in a competing-risks survival model. Because of the small numbers of women lost to follow-up in
Nigeria (n = 3 at 3 years), Nigeria was not included in this analysis.
b SHR estimated from a competing-risk regression model with death as a competing event, adjusted for population group
(Uganda and Namibia), tumor stage at diagnosis, socioeconomic position, and age (linear increase per year).
c Assessed comorbid conditions included hypertension, diabetes, chronic obstructive pulmonary disease, hepatitis, heart
disease, anemia, asthma, and tuberculosis.
d Lower than tertiary level.
e Including 277 housewives.
f Values were missing in Namibia due to a data collection error. There were 12 missing values for employment and 33 missing
values each for belief in spiritual medicine and belief in traditional medicine.
Figure 3. Cumulative proportion of time between the occurrence of a death and the study investigators’ being informed of the death (median
lag time), by country, African Breast Cancer—Disparities in Outcomes Study, 2014–2018.
across the 4 countries to reasonably attribute the few LTFU
to the mHealth approach. It must be acknowledged, how-
ever, that the follow-up approach was not evaluated in a
randomized controlled trial; thus, the low LTFU may not
have been entirely due to the follow-up methodology but
may additionally have partially reflected other features of the
study, such as the particular settings, motivation of women,
and study personnel.
Generally, LTFU in retrospective studies that rely entirely
on medical records are clinical losses, and thus there is a
risk of overestimating survival if women LTFU are actually
deaths occurring due to no treatment or incomplete treat-
ment. In ABC-DO, study LTFUs are necessarily also clinical
losses; however, use of the mHealth methodology ensured
that the reverse was not true—that is, not all clinical losses
were study losses. A recent publication documented a high
percentage (20%, particularly affecting low-socioeconomic-
status groups) of untreated women, especially in Nigeria,
despite its very few statistical LTFU (19).
Implementing mHealth follow-up
The low percentage of LTFU achieved in ABC-DO makes
the active mHealth follow-up approach an attractive method.
The availability of multiple phone numbers for patients
and their NOK helped the study investigators to maintain
contact with participants. Initial concerns that the high reg-
ularity of contact might become a nuisance to women were
not realized; on the contrary, the study research assistants
reported that for many women, being part of the ABC-DO
Study was accompanied by a sense of belonging and ex-
periencing psychosocial support. Although the study was
intended to be observational, it would have been unethical to
withhold advice from women during the prospective follow-
up contact, though no specific intervention or training of
research nurses was part of the protocol. Occasionally nurses
informed women about the importance of completing their
Comparison with previous findings
Compared with other recent studies of breast cancer sur-
vival in SSA, LTFUs in ABC-DO were low (Web Figure 
2). Only a few previous cohorts were prospectively follow-
ed. In one study by Kantelhardt et al. (6), follow-up was 
passive, relying on data captured during routine hospital 
visits. The percentage LTFU was 22% after 2 years, despite 
the study’s free provision of endocrine treatment to breast 
cancer patients. Generally, most previous studies had retro-
spective designs (7, 11–13, 18). Particularly high losses, of 
up to 45%, were reported in studies that relied on follow-
up through hospital records alone (7, 11, 13). In recently 
published breast cancer survival estimates from 14 registries 
in the African Cancer Registry Network, combining retro-
spective data collection with active tracing of lost cases, 
most LTFU estimates were over 20% (12). Only 3 settings 
achieved few LTFU at 3 years (Mauritius, Seychelles, and 
Zimbabwe-Harare), and 2 of these (Mauritius, Seychelles) 
were higher-income settings with high-quality population-
based cancer and, in Mauritius, mortality registers and thus 
do not depict typical situations across SSA. Sensitivity anal-
yses of worst- and best-case scenarios can be conducted to 
assess the likely impact of LTFU on survival estimates; how-
ever, with large LTFU, they increase uncertainty and produce 
considerably different survival estimates (e.g., an estimate of 
an absolute difference of 15 percentage points at 2 years (6)). 
Across previous studies, definitions of LTFU differed. Most 
publications lacked this information, and where available, 
the predominant definition was “unknown vital status at the 
censoring date.” With the exception of 1 other study (11), 
LTFU percentages were presented in raw numbers instead 
of accounting for deaths as competing events as we did. 
Nevertheless, despite these differences in methodology, the 
differences in LTFU between the present study’s prospec-
tive mHealth follow-up approach and other approaches was 
sufficiently large in magnitude and sufficiently consistent
treatment or the possibilities of finding financial support if
asked, and therefore they increased compliance and presum-
ably reduced clinical and study losses.
mHealth in ABC-DO incorporated a programmed study
management protocol, which prompted research assistants
about when to call each woman. This system ensured smooth
and time-efficient adherence to the study protocol and pro-
vided real-time data for a dynamic cohort. As an asset of
the mHealth application used in ABC-DO, only the research
assistant’s phones/tablets needed to be smartphones; partic-
ipants’ phones could be basic handsets.
Although mHealth produced low LTFU overall, 1 ABC-
DO site experienced significant losses. In Zambia, a change
in study personnel led to irreversible losses, emphasizing
the need for regularity of contact. Other challenges con-
cerned changing phone numbers. SSA has the world’s fastest
emerging telecommunications market, with competing
providers attracting customers with new offers; thus, mul-
tiple subscriber identity module (SIM) cards and regular
changes of phone numbers are common. During the study
period, authorities were also tightening the regulation of
SIM card registration. For example, in Uganda, unregistered
SIM cards are periodically deactivated (e.g., in March 2017).
Despite this, in ABC-DO we did not detect a specific in-
crease in LTFU subsequent to these dates, and a discontinued
mobile phone number was the reported reason for LTFU in
only a few instances. Even when a mobile phone number
was valid, contact was occasionally challenging for women
residing in very remote areas where network coverage, even
third-generation (3G) mobile telecommunications technol-
ogy, was poor (19). In a vast country like Namibia, there
are areas with poor network coverage. However, local
study teams report that the basic Global System for Mobile
Communications (GSM) network (second-generation (2G))
was available for almost all women within a reasonable
distance. Another consideration for use of mHealth contact
is a supply of electricity with which to recharge phones.
Power banks were provided to study personnel, but partici-
pants’ phones were occasionally affected, since power out-
ages in the study area can last more than a week. With the
combination of these obstacles, repeated contact attempts
were made, and discretion was used prior to and when con-
tacting a participant’s NOK. In contrast, we did not ex-
perience other concerns, such as phone theft, and because
we did not use text messaging to contact women, breaches
of confidentiality were not encountered (20). In addition,
the design ensured no follow-up costs to patients. Once the
mHealth app was programmed, the running costs included
data-hosting charges and an annual contract to a phone
provider with a maximal call and data time. One full-time
research assistant was able to follow up to 300 women.
Profile of women LTFU
Characteristics of women LTFU in cancer cohorts in SSA
are rarely described. In the ABC-DO Study, younger age
(<35 years) was a risk factor for being LTFU, a finding
consistent across countries. Previous findings from ABC-
DO have shown that stage at diagnosis was slightly more
advanced in younger women (21), and very young women
also have lower survival; thus, some of the women LTFU
may have died. Study nurses felt that other reasons for
these losses might have been sociocultural—for example,
the family may have been ashamed of the death or may have
still been in mourning and did not want to answer the phone.
Such losses may also have occurred simply due to more
frequent changes of the mobile phone number. In ABC-DO,
more losses occurred among women with missing tumor
stage data (15 of 99), but where stage was known, losses
were not higher in women with more advanced disease,
as has been seen in previous studies (11). Considering that
missing stage information might indicate very advanced dis-
ease or a woman’s being too fragile for diagnostic workup,
such a finding should be kept in mind for studies where this
subgroup is large. In Zambia, women of lower socioeco-
nomic position were more likely to be LTFU, which may
also arise from lower survival, because in ABC-DO, an ac-
cumulation of social disadvantages has been identified as a
major barrier to early diagnosis through a long prediagnostic
journey, and is a barrier to receiving breast cancer treatment
(22). Finally, HIV-positive women in Zambia were less
likely to be LTFU. This finding is probably due to the more
frequent health-care contacts among these women.
Research implications
Few losses and timely death ascertainment achieved via
mHealth research methodology are desirable features for all
cancer cohorts. Follow-up methods may need to be adjusted
for the cancer and setting in question. For cancers with
a poorer prognosis, contact intervals and total follow-up
time may need to be reduced to capture deaths in a timely
fashion. A prospective study design was essential in the
mHealth approach adopted in ABC-DO; thus, applications
of mHealth to population-based studies would require access
to a patient’s phone number and rapid case identification
to initiate follow-up. A further consideration in applying
mHealth follow-up is the outcome of interest. For the
outcome of death from all causes, vital status information
provided by a family member or NOK can be considered
reliable, but if cause-specific information on mortality is
needed, validation of an NOK’s reported cause of death
or other sources of this information would be needed.
Data on other cancer endpoints, such as progression-free or
metastasis-free survival, would be difficult to capture in a
phone call to a layperson. Examination of such outcomes
may be better pursued through the conduct of smaller-
scale in-depth clinical studies with physical patient recall to
incorporate physical, imaging, and biomarker evaluations.
Nevertheless, because survival rates for most cancers in SSA
currently lag considerably behind those of higher-income
countries, the hard outcome of death from all causes remains
a valuable one at present, for which an mHealth follow-up
approach is effective in large-scale studies.
Of greater importance than mHealth for research follow-
up is the potential for mHealth to improve patient sur-
vival and clinical follow-up. Thus, the success of prospec-
tive mHealth follow-up may be an avenue through which
improvements in treatment completion and survival can be
achieved. Mobile technologies could be used not only for
giving advice and appointment reminders to women but also,
in the African setting, for money transfers if transportation
costs and other costs are prohibiting continuation of treat-
ment. Randomized trials are needed to evaluate whether use
of mHealth can improve survival in such a fashion.
In summary, mHealth technologies have the potential to
transform cancer survival studies in low-resource settings
through real-time, high-quality follow-up data with minimal
LTFUs and timely ascertainment of deaths.
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